All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @masteringdiabetes on TikTok · 57s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @masteringdiabetes's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00It's official. Ozempic is downright dangerous. Don't believe me? Watch until the end and I'll show you
  2. 0:05exactly why. While weight loss can bring about significant health benefits, it's also important to
  3. 0:09note that rapid weight loss, which is what Somaglitide promotes, can have negative consequences,
  4. 0:15including but not limited to a decrease in muscle mass, lower bone density, and a decrease in
  5. 0:20resting metabolic rate. However, in addition to lean body mass, there's other GI issues that
  6. 0:25also come to the surface, including constipation, diarrhea, nausea, vomiting, and abdominal pain,
  7. 0:30as well as feeling excessively full, excessive bloating, and belching as well as heartburn.
  8. 0:35They also found that the use of GLP1 receptor agonists increased the risk of gastroparesis,
  9. 0:40which is a stomach paralysis, by 3.67 times. And that condition can be extremely painful,
  10. 0:46and there is no known cure. That condition restricts the passage of food from the stomach to the
  11. 0:51small intestine, and that can result in symptoms like vomiting, diarrhea, and abdominal pain.

@masteringdiabetes's Ozempic side effects list, fact-checked

masteringdiabetes

TikTok creator

32.6K viewsWatch on TikTok

Quick answer

Semaglutide (Ozempic/Wegovy) carries a well-documented GI side effect profile that is dose-dependent and most prominent during titration, with rates of nausea reaching roughly 44% in STEP trials but typically declining over time. A 2023 retrospective study by Sodhi et al. in JAMA identified a statistically significant association between GLP-1 receptor agonists and gastroparesis risk, but absolute event rates were low and the study design limits causal conclusions. Clinicians generally weigh these risks against semaglutide's established cardiovascular and metabolic benefits, which the video does not address.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 10 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @masteringdiabetes's Ozempic side effects list, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@masteringdiabetes's Ozempic side effects list, fact-checked" from masteringdiabetes. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide (Ozempic/Wegovy) carries a well-documented GI side effect profile that is dose-dependent and most prominent during titration, with rates of nausea reaching roughly 44% in STEP trials but typically declining over time.

The reason this review is not generic is the source wording and the canonical claim label "glp1 ozempic can help you lose weight but have you considered th." In this clip, the useful excerpt is: "It's official." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The 3.
People who land here are usually trying to understand whether the Compounded Semaglutide claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Semaglutide (Ozempic/Wegovy) carries a well-documented GI side effect profile that is dose-dependent and most prominent during titration, with rates of nausea reaching roughly 44% in STEP trials but typically declining over time.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Semaglutide (Ozempic/Wegovy) carries a well-documented GI side effect profile that is dose-dependent and most prominent during titration, with rates of nausea reaching roughly 44% in STEP trials but typically declining over time. A 2023 retrospective study by Sodhi et al. in JAMA identified a statistically significant association between GLP-1 receptor agonists and gastroparesis risk, but absolute event rates were low and the study design limits causal conclusions. Clinicians generally weigh these risks against semaglutide's established cardiovascular and metabolic benefits, which the video does not address.
  • In STEP 1 trial data (Wilding et al., 2021, NEJM), 44% of semaglutide users reported nausea, but rates declined significantly after the titration phase ended.
  • The 3.67x gastroparesis risk (Sodhi et al., 2023, JAMA) is a relative risk from a retrospective study, not a clinical trial, and absolute event rates in the study were still low.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • In STEP 1 trial data (Wilding et al., 2021, NEJM), 44% of semaglutide users reported nausea, but rates declined significantly after the titration phase ended.
  • The 3.67x gastroparesis risk (Sodhi et al., 2023, JAMA) is a relative risk from a retrospective study, not a clinical trial, and absolute event rates in the study were still low.
  • Semaglutide reduced major cardiovascular events by 20% in adults with obesity without diabetes (Lincoff et al., 2023, NEJM), a benefit this video does not mention.
  • Lean muscle loss during semaglutide treatment is documented but is consistent with other caloric-deficit weight loss methods and is not a drug-specific phenomenon.
  • Most GI side effects from semaglutide are dose-dependent and transient, which is why clinical protocols involve slow dose titration over several months.
  • Gastroparesis is a serious condition, but presenting it alongside common side effects like nausea without frequency context misleads viewers about the actual likelihood of that outcome.
  • Anyone considering or currently taking a GLP-1 medication should discuss their GI history, thyroid history, and strategies for preserving muscle mass with a licensed clinician, not base decisions on TikTok framing.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @masteringdiabetes actually say?

The creator opened with a strong declaration: Ozempic is "downright dangerous." From there, the video listed real GI side effects, raised concerns about muscle and bone loss from rapid weight loss, and cited a statistic that GLP-1 receptor agonists increase the risk of gastroparesis by 3.67 times. The framing was clearly designed to discourage use, ending with a pointed "you decide whether to take it or not."

To be fair, the side effects listed, including constipation, nausea, vomiting, diarrhea, and abdominal pain, are documented in the prescribing information and in clinical trials. The gastroparesis statistic is also drawn from a real study. But the framing around all of it inflates risk and strips context in ways that could mislead people who are weighing a legitimate medical treatment.

Does the science back this up?

Partially. The GI side effects are real and well-documented, but the gastroparesis risk stat needs serious context before it lands the way the creator intends. The 3.67x figure comes from a real, peer-reviewed source, but it's a relative risk from a retrospective study, not a clinical trial.

The claim that semaglutide "promotes rapid weight loss" with consequences like muscle loss and lower bone density is also partially accurate but painted too broadly. Lincoff et al. (2023, New England Journal of Medicine) found that semaglutide reduced cardiovascular events by 20% in people with obesity, a benefit the video ignores entirely. Studies like Wadden et al. (2021, NEJM) documented that weight loss on semaglutide averaged about 15% of body weight over 68 weeks. That is not the same as crash dieting. The rate matters when assessing muscle loss risk, and the creator does not acknowledge resistance training or protein intake as mitigating factors.

What did they get wrong (or right)?

Credit where it is due: the list of GI side effects is accurate. The FDA label for semaglutide lists nausea, diarrhea, vomiting, constipation, and abdominal pain as the most common adverse reactions, and clinical trial data from SUSTAIN and STEP programs back that up. Belching, heartburn, and bloating are also reported, though less frequently.

Where the creator stumbles is the gastroparesis framing. The 3.67x risk figure comes from Sodhi et al. (2023, JAMA), a retrospective cohort study using insurance claims data. The absolute risk of gastroparesis in that study was still low, and the authors themselves flagged limitations including potential misclassification. The creator describes gastroparesis as having "no known cure" and leaves it there, which is technically true in the sense that there is no universally effective treatment, but it implies that patients on semaglutide face this as a likely outcome. They do not.

The claim that semaglutide causes "stomach paralysis" as a routine side effect is misleading. Most GI symptoms with semaglutide are dose-dependent and transient. Presenting gastroparesis in the same breath as nausea and bloating obscures a significant difference in frequency and severity.

What should you actually know?

GI side effects from semaglutide are common, especially in the first few weeks of treatment or after a dose increase. Most are manageable and tend to resolve. Starting at a low dose and titrating slowly is standard clinical practice precisely because of this. The gastroparesis signal is real and worth monitoring, but it is not the inevitable endpoint the video implies.

The concern about lean muscle mass is legitimate and shared by many clinicians. Wilding et al. (2021, NEJM) noted that weight loss from semaglutide includes both fat and lean mass, consistent with most caloric-restriction approaches. This is a real consideration, especially for older adults. It is not unique to semaglutide and does not make the drug "downright dangerous."

If you are considering a GLP-1 medication, the actual questions to ask a clinician include your personal GI history, your risk for pancreatitis or a family history of medullary thyroid carcinoma, and how to preserve muscle mass through diet and exercise. Those are not questions this video helps you answer.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

masteringdiabetes · TikTok creator

32.6K views on this video

Ozempic can help you lose weight, but have you considered the side effects? They include: 👉 Constipation 👉 Diarrhea 👉 Nausea 👉 Vomiting 👉 Abdominal pain There are also other GI issues to watch ou

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about in step 1 trial data (wilding et al., 2021, nejm),?

In STEP 1 trial data (Wilding et al., 2021, NEJM), 44% of semaglutide users reported nausea, but rates declined significantly after the titration phase ended.

What does the video say about the 3.67x gastroparesis risk (sodhi et al., 2023, jama)?

The 3.67x gastroparesis risk (Sodhi et al., 2023, JAMA) is a relative risk from a retrospective study, not a clinical trial, and absolute event rates in the study were still low.

What does the video say about semaglutide reduced major cardiovascular events by 20% in adults with?

Semaglutide reduced major cardiovascular events by 20% in adults with obesity without diabetes (Lincoff et al., 2023, NEJM), a benefit this video does not mention.

What does the video say about lean muscle loss during semaglutide treatment?

Lean muscle loss during semaglutide treatment is documented but is consistent with other caloric-deficit weight loss methods and is not a drug-specific phenomenon.

What does the video say about most gi side effects from semaglutide?

Most GI side effects from semaglutide are dose-dependent and transient, which is why clinical protocols involve slow dose titration over several months.

What does the video say about gastroparesis?

Gastroparesis is a serious condition, but presenting it alongside common side effects like nausea without frequency context misleads viewers about the actual likelihood of that outcome.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by masteringdiabetes, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.